Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Fosun Pharma (02696.HK) HLXTEHAase02 Injection Clinical Trial Approved
Recommend 2 Positive 0 Negative 1 |
||||
|
||||
|
Fosun Pharma (02696.HK) announced that the Phase 1 clinical trial application (IND) for its independently developed HLXTEHAase02 (recombinant human hyaluronidase injection) has been approved by the National Medical Products Administration (NMPA). The company plans to conduct the related clinical trials within mainland China (excluding Hong Kong, Macau, and Taiwan) once conditions permit. HLXTE-HAase02 is a novel recombinant human hyaluronidase (rHuPH20) independently developed by the company, intended to enhance the diffusion and absorption of drugs administered via subcutaneous injection or infusion. This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
